@article{PinkRichterGerdesetal.2014, author = {Pink, Daniel and Richter, Stephan and Gerdes, Sebastian and Andreou, Dimosthenis and Tunn, Per-Ulf and Busemann, Christoph and Ehninger, Gerhard and Reichardt, Peter and Schuler, Markus K.}, title = {Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis}, journal = {Oncology}, volume = {87}, number = {2}, issn = {0030-2414}, doi = {10.1159/000362602}, url = {www.karger.com/ocl}, institution = {Kliniken und Polikliniken f{\"u}r Innere Medizin}, pages = {95 -- 103}, year = {2014}, abstract = {Objective: Epithelioid sarcoma (ES) presents unique clinical features in comparison to other sarcoma subtypes. Data regarding the benefits of chemotherapy are very limited. Combination regimens using gemcitabine and docetaxel (Gem/Doce) have proven to be effective, especially in uterine and nonuterine leiomyosarcoma. Yet, there is no available data on the efficacy of Gem/Doce in ES. Methods: A retrospective analysis of the three participating institutions was performed. Twenty-eight patients with an ES diagnosis presented at one of the participating institutions between 1989 and 2012. Of this group, 17 patients received chemotherapy. Results: Patients' median overall survival (OS) after the beginning of palliative chemotherapy was 21 months, and the 1-year OS was 87\%. Twelve patients received Gem/Doce with a clinical benefit rate of 83\%. The median progression-free survival (PFS) was 8 months for all patients receiving Gem/Doce. The best response was complete remission in 1 patient and partial remission in 6 patients. All 6 patients receiving Gem/Doce as a first-line treatment showed measurable responses with a median PFS of 9 months. Conclusions: In this retrospective study, Gem/Doce was an effective chemotherapeutic regimen for ES. Prospective studies are needed to better assess the effects of this combination drug therapy.}, subject = {-}, language = {en} }